Cargando…
Extensive Gray Matter Volume Reduction in Treatment-Resistant Schizophrenia
BACKGROUND: Approximately one-third of people with schizophrenia are treatment-resistant and some do not achieve remission with clozapine, the gold-standard antipsychotic medication for treatment-resistant schizophrenia. This study compared global and regional brain volumes between treatment-respond...
Autores principales: | Anderson, Valerie M, Goldstein, Meghan E, Kydd, Robert R., Russell, Bruce R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4540109/ https://www.ncbi.nlm.nih.gov/pubmed/25716781 http://dx.doi.org/10.1093/ijnp/pyv016 |
Ejemplares similares
-
Glutamatergic Neurometabolites in Clozapine-Responsive and -Resistant Schizophrenia
por: Goldstein, Meghan Elizabeth, et al.
Publicado: (2015) -
Widespread reductions in gray matter volume in depression()
por: Grieve, Stuart M., et al.
Publicado: (2013) -
Insular Gray Matter Volume and Objective Quality of Life in Schizophrenia
por: Uwatoko, Teruhisa, et al.
Publicado: (2015) -
Emotional Awareness in Schizophrenia Is Associated With Gray Matter Volume of Right Precuneus
por: Jáni, Martin, et al.
Publicado: (2021) -
Kynurenine pathway metabolites are associated with gray matter volume in subjects with schizophrenia
por: Zhou, Sumiao, et al.
Publicado: (2022)